MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the sale of
future royalties, net
$392M
Proceeds from the
issuance of common stock...
$80M
Proceeds from the
issuance of common stock...
$6M
Proceeds from maturities
of marketable...
$444M
Net cash provided by
financing activities
$478M
Net cash provided by
(used in) investing...
$236M
Effect of exchange rate
changes on cash
$4M
Canceled cashflow
$208M
Net increase
(decrease) in cash, cash...
$252M
Canceled cashflow
$466M
Stock-based compensation
$153M
Non-cash interest
expense on liabilities...
$62M
Depreciation and
amortization
$35M
Accounts payable,
accrued, and other...
$24M
Purchase of marketable
securities
$186M
Payments for intangible
asset
$15M
Purchase of property,
plant, and equipment
$6M
Other
$1M
Net cash used in
operating activities
-$466M
Canceled cashflow
$274M
Net loss
-$575M
Non-cash royalty revenue
$112M
Accounts receivable
$31M
Prepaid expenses and
other assets
$10M
Inventory
$6M
Amortization of discount on
marketable securities, net
$4M
Other
$2M
Back
Back
Cash Flow
source: myfinsight.com
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)